NCLifeSci Blog
Stay up to date with the latest from NCLifeSci
Recent Posts
A new report from the North Carolina State Treasurer found North Carolina hospitals use the federal 340B program to profit at the expense of patients, teachers and state employees. Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that…
Read MoreNorth Carolina is a leading hub of medical innovation. Our state is home to elite research universities, state-of-the-art laboratories, and over 800 biopharmaceutical companies that employ more than 75,000 residents. Our life sciences industry generates $2.4 billion in state and local government revenue every year. But this thriving innovation economy is at risk, thanks to…
Read MoreA 2022 tax rule requiring the amortization of research and development expenses has created significant challenges for many life sciences startups and small businesses. Previously, grant money received by these companies and spent on R&D could be deducted immediately in full, but the new rule forces them to spread the deduction over five years for…
Read MoreThe small red bump on my son’s hand looked at first like a bug bite. But when the hand swelled to the point of immobility and we took him to the doctor, the diagnosis was MRSA, an infection from a type of staph bacteria resistant to the family of antibiotics usually prescribed as treatments. Thankfully,…
Read MoreA new study estimates that there would be 237 fewer FDA approvals of new medicines over the next decade and 1.1 million lost jobs if proposals to expand government-mandated drug pricing policies are implemented.
Read MoreThe rarest day on the calendar is the one that does not even occur in every year: February 29. In 2008, this was designated as Rare Disease Day and since then, the last day of February has been an opportunity to draw attention to, honor and support people living with these conditions.
Read MoreThe World Trade Organization is considering continuing to waive certain intellectual property rights on COVID-19 diagnostics and therapeutics, following a recent decision to do the same for vaccines.
Read MoreEvery member of the Council of State Bioscience Associations signed a letter to President Joe Biden expressing serious concerns with the proposed expansion of IP protections for COVID technology.
Read MoreCongress passed the Inflation Reduction Act on Aug. 12. Included in the law is a provision that gives Medicare Part D the ability to “negotiate” the price of medicines for the first time. Negotiate is in quotation marks because lawmakers are being ironic; no one can legitimately call the new price-setting policy a negotiation.
Read MoreOn April 7, the Centers for Medicare and Medicaid Services held to its original decision to limit coverage of the Biogen’s Alzheimer’s disease treatment Aduhelm – along with other drugs like it – to clinical trials. Michelle McMurry-Heath, M.D., Ph.D., president and CEO of the Biotechnology Innovation Organization, released the following statement: “The National Coverage…
Read More